Deutsche Bank AG Decreases Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Key Points

• Deutsche Bank AG reduced its stake in IQVIA Holdings Inc. by 9.8%, now holding 739,779 shares valued at $130.42 million.
• Several institutional investors significantly increased their positions in IQVIA, with Pacer Advisors raising its stake by 5,036.1%, acquiring 871,704 shares valued at $153.68 million.
• Analysts have mixed evaluations of IQVIA, with JPMorgan lowering its target price from $232.00 to $177.00, while UBS increased its target from $185.00 to $225.00, contributing to a consensus rating of "Moderate Buy".

Deutsche Bank AG lowered its stake in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 9.8% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 739,779 shares of the medical research company's stock after selling 80,130 shares during the period. Deutsche Bank AG owned about 0.43% of IQVIA worth $130,423,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently modified their holdings of the business. Continuum Advisory LLC increased its position in IQVIA by 3.7% during the fourth quarter. Continuum Advisory LLC now owns 1,803 shares of the medical research company's stock worth $354,000 after acquiring an additional 64 shares during the period. Ballentine Partners LLC increased its holdings in IQVIA by 4.9% in the 1st quarter. Ballentine Partners LLC now owns 1,477 shares of the medical research company's stock valued at $260,000 after buying an additional 69 shares during the period. ST Germain D J Co. Inc. lifted its position in shares of IQVIA by 66.1% during the 1st quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company's stock worth $34,000 after buying an additional 76 shares during the period. Nemes Rush Group LLC grew its holdings in shares of IQVIA by 15.0% in the 1st quarter. Nemes Rush Group LLC now owns 621 shares of the medical research company's stock worth $109,000 after purchasing an additional 81 shares during the last quarter. Finally, Atria Wealth Solutions Inc. grew its holdings in shares of IQVIA by 5.6% in the 1st quarter. Atria Wealth Solutions Inc. now owns 1,812 shares of the medical research company's stock worth $319,000 after purchasing an additional 96 shares during the last quarter. Hedge funds and other institutional investors own 89.62% of the company's stock.

Insider Buying and Selling at IQVIA

In other IQVIA news, insider Keriann Cherofsky sold 549 shares of the firm's stock in a transaction dated Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total value of $105,149.97. Following the completion of the transaction, the insider owned 2,910 shares in the company, valued at $557,352.30. This trade represents a 15.87% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Eric Sherbet sold 5,800 shares of the firm's stock in a transaction dated Wednesday, July 23rd. The stock was sold at an average price of $190.05, for a total value of $1,102,290.00. Following the completion of the transaction, the insider owned 27,178 shares of the company's stock, valued at approximately $5,165,178.90. This represents a 17.59% decrease in their position. The disclosure for this sale can be found here. Company insiders own 1.60% of the company's stock.

IQVIA Trading Up 3.3%

Shares of IQVIA stock traded up $6.03 on Tuesday, reaching $186.12. 1,487,624 shares of the company's stock were exchanged, compared to its average volume of 2,371,880. IQVIA Holdings Inc. has a 52 week low of $134.65 and a 52 week high of $252.88. The firm's 50-day moving average is $167.92 and its two-hundred day moving average is $168.89. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.84 and a current ratio of 0.84. The company has a market capitalization of $31.64 billion, a P/E ratio of 26.93, a price-to-earnings-growth ratio of 1.98 and a beta of 1.30.

IQVIA (NYSE:IQV - Get Free Report) last released its quarterly earnings results on Tuesday, July 22nd. The medical research company reported $2.81 EPS for the quarter, beating analysts' consensus estimates of $2.77 by $0.04. The business had revenue of $4.02 billion during the quarter, compared to analyst estimates of $3.96 billion. IQVIA had a return on equity of 30.05% and a net margin of 7.88%. IQVIA's quarterly revenue was up 5.3% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.64 EPS. Sell-side analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the stock. Evercore ISI upped their target price on shares of IQVIA from $170.00 to $180.00 and gave the stock an "outperform" rating in a report on Wednesday, July 9th. Mizuho increased their price objective on shares of IQVIA from $190.00 to $225.00 and gave the stock an "outperform" rating in a report on Friday, July 25th. HSBC lowered shares of IQVIA from a "buy" rating to a "hold" rating and decreased their price objective for the stock from $260.00 to $160.00 in a report on Friday, April 25th. Robert W. Baird upped their target price on shares of IQVIA from $159.00 to $196.00 and gave the company a "neutral" rating in a research report on Wednesday, July 23rd. Finally, Hsbc Global Res lowered shares of IQVIA from a "strong-buy" rating to a "hold" rating in a research note on Friday, April 25th. Seven investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $228.62.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.